Global Biopharma CEOs Frustrated By IP Waiver Talk Amid COVID-19 Vaccine Glut
Executive Summary
Top pharma executives claim ongoing vaccine inequity is not due to a lack of supply but to a shortage of sufficient infrastructure in low-and-middle income countries to administer available doses.
You may also be interested in...
What Vexed Top Global Biopharmaceutical Executives About COVID-19 Response
Pfizer, Eli Lilly and Roche bosses say no country was perfect in its response to the coronavirus pandemic and there are lessons to be learnt.
Coronavirus Notebook: Hearings On Pandemic Treaty Begin, New Risk-Sharing Partnership To Boost COVAX Efforts
Médecins Sans Frontières says the latest draft of the proposed IP waiver must be rejected, and the WHO has suspended supply of Bharat’s COVID-19 vaccine over manufacturing issues. Two EU agencies have issued advice on fourth doses of mRNA vaccines, while GlaxoSmithKline has filed high-dose sotrovimab for patients with suspected Omicron BA.2 infection in Australia.
Coronavirus Notebook: 35 Generic Firms To Produce Pfizer’s Paxlovid, AZ’s Evusheld Gains UK & Australian Approval
Finland’s Rokote expects to begin clinical trials with its intranasal vaccine after the summer, while Australia’s ENA Respiratory has dosed the first patients in a Phase IIa study of its antiviral nasal spray.